IXICO Final Earnings Report

IXICO EPS Results

• Actual EPS: -GBX 4.14
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

IXICO Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

IXICO Announcement Details

• Quarter: Final
• Date: 12/4/2024
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

IXICO (LON:IXI) is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials. The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Image data is interrogated by the Platform and IXICO’s expert scientists translating complex data into clinically meaningful while minimising data variability and increasing reproducibility. The approach enables research scientists to make better informed decisions earlier in the drug development process. The Company is an expert iCRO and technology partner in neuroimaging, pioneering new capabilities in neurodegeneration biomarker research such as vascular pathology in AD and the measurement of Neuromelanin accumulation in PD and inflammatory processes across neurodegenerative diseases. IXICO’s mission is advance medicine and patient outcomes through the sophisticated measurement and analysis of existing and previously inaccessible disease signalling biology. The latest generation of the Platform positions IXICO’s technology beyond its traditional iCRO remit and opens opportunities to expand into diagnostics, mechanistic disease understanding, patient selection/stratification, pre-clinical drug candidate validation, post-marketing surveillance and clinical decision support. IXICO’s technology is being used every day across the world. Clients and partners use IXICO for its advanced technology, scientific expertise and service excellence. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world. The Company is dedicated to delivering better outcomes for patients and is a key part of the global neurological disease research community with a proven track record in the biopharmaceutical industry working with leading pharma companies, innovative biotech’s, disease consortia and non-profit organisations. As the prevalence and understanding of neurological conditions increases there is an urgent need to find better treatments. Neurological conditions are now the leading cause of disability worldwide and the second leading cause of death after cardiovascular disease. Approximately 3.4 billion people, equivalent to 43% of the global population, were affected by conditions impacting the nervous system. AD is believed to affect more than 55 million people globally, a figure projected to reach 78 million by 2030. PD is the second most prevalent neurodegenerative condition after AD with global, estimates projecting that more than 10 million people are living with the disease.